Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685008 · ClinicalTrials.gov registry record · Phase 2
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by MorphoSys.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT01685008: Completed Phase 2 study of Non-Hodgkin Lymphoma, sponsored by MorphoSys.
NCT01685008 is a Phase 2 study of Non-Hodgkin Lymphoma that has completed, run by MorphoSys. The registered enrollment target is 92 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01685008, a Phase 2 study of Non-Hodgkin Lymphoma, has completed, sponsored by MorphoSys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).
Primary Outcome
Proportion of patients with Complete Remission (CR; disappearance of all evidence of disease) or Partial Remission (PR; regression of measurable disease and no new sites), assessed as per the 2007 International Working Group (IWG) response criteria by radiographic evaluations (CT, PET, MRI, or other).
Conditions Studied
Interventions
- DRUG MOR00208 (formerly Xmab 5574)
Study Locations (20)
Other
- MorphoSys Research Site - Brussels
- MorphoSys Research Site - Edegem
- MorphoSys Research Site - Berlin
- MorphoSys Research Site - Mainz
- Morphosys Research Site - Ulm
- Morphosys Research Site - Budapest
- Morphosys Research Site - Debrecen
- MorphoSys Research Site - Bologna
- MorphoSys Research Site - Florence
- Morphosys - Genova
- Morphosys Research Site - Modena
- Morphosys Research Site - Novara
- MorphoSys Research Site - Chorzów
- Morphosys Research Site - Krakow
- Morphosys Research Site - Lódz
- MorphoSys Research Site - Słupsk
Connecticut
- MorphoSys Research Site - Norwalk
New Jersey
- MorphoSys Research Site - Hackensack
Ohio
- Morphosys Research Site - Columbus
Texas
- Morphosys Research Site - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-04-23 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 2 |
What the finished NCT01685008 record still lists
NCT01685008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which MOR00208 (formerly Xmab 5574) is the first listed.
NCT01685008 names 20 study sites across 5 states, led by Other, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01685008 about?
NCT01685008 is a clinical study titled "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)". This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).
What is the current status of trial NCT01685008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-04-23. Estimated completion is 2022-04-06.
What conditions does trial NCT01685008 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT01685008?
The interventions under investigation include: MOR00208 (formerly Xmab 5574) (DRUG).
Who is sponsoring clinical trial NCT01685008?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01685008 being conducted?
This trial has 20 study locations across Connecticut, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01685008's enrollment target sits among peer trials
92 41st of 106 higher than 66 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI